Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

Ranee Chatterjee, Laine Thomas, Laura Svetkey, Frederick L. Brancati, Robert M. Califf, David Edelman

Research output: Contribution to journalArticle

Abstract

BACKGROUND Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium.METHODSWe analyzed data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, which randomized participants at risk for diabetes to either valsartan (up to 160mg daily) or no valsartan. Using Cox models, we evaluated the effect of valsartan on diabetes risk over a median of 4 years of follow-up and calculated the mediation effect of serum potassium as the difference in treatment hazard ratios from models excluding and including 1-year change in serum potassium. The 95% confidence interval (CI) for the difference in log hazard ratios was computed by bootstrapping.RESULTSThe hazard ratio for developing diabetes among those on valsartan vs. no valsartan was 0.866 (95% CI = 0.795-0.943) vs. 0.868 (95% CI = 0.797-0.945), after controlling for 1-year change in potassium. The bootstrap 95% CI for a difference in these log hazard ratios was not statistically significant (-0.003 to 0.009).CONCLUSIONSSerum potassium does not appear to significantly mediate the protective effect of valsartan on diabetes risk.

Original languageEnglish (US)
Pages (from-to)723-726
Number of pages4
JournalAmerican Journal of Hypertension
Volume26
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Valsartan
nateglinide
Glucose Intolerance
Potassium
Outcome Assessment (Health Care)
Confidence Intervals
Serum
Proportional Hazards Models

Keywords

  • blood pressure
  • diabetes
  • hypertension
  • risk
  • serum potassium
  • valsartan.

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of changes in potassium with valsartan use on diabetes risk : Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. / Chatterjee, Ranee; Thomas, Laine; Svetkey, Laura; Brancati, Frederick L.; Califf, Robert M.; Edelman, David.

In: American Journal of Hypertension, Vol. 26, No. 6, 06.2013, p. 723-726.

Research output: Contribution to journalArticle

Chatterjee, Ranee ; Thomas, Laine ; Svetkey, Laura ; Brancati, Frederick L. ; Califf, Robert M. ; Edelman, David. / Effects of changes in potassium with valsartan use on diabetes risk : Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. In: American Journal of Hypertension. 2013 ; Vol. 26, No. 6. pp. 723-726.
@article{16349e899a6f4538aa8e1b1878ae6665,
title = "Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial",
abstract = "BACKGROUND Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium.METHODSWe analyzed data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, which randomized participants at risk for diabetes to either valsartan (up to 160mg daily) or no valsartan. Using Cox models, we evaluated the effect of valsartan on diabetes risk over a median of 4 years of follow-up and calculated the mediation effect of serum potassium as the difference in treatment hazard ratios from models excluding and including 1-year change in serum potassium. The 95{\%} confidence interval (CI) for the difference in log hazard ratios was computed by bootstrapping.RESULTSThe hazard ratio for developing diabetes among those on valsartan vs. no valsartan was 0.866 (95{\%} CI = 0.795-0.943) vs. 0.868 (95{\%} CI = 0.797-0.945), after controlling for 1-year change in potassium. The bootstrap 95{\%} CI for a difference in these log hazard ratios was not statistically significant (-0.003 to 0.009).CONCLUSIONSSerum potassium does not appear to significantly mediate the protective effect of valsartan on diabetes risk.",
keywords = "blood pressure, diabetes, hypertension, risk, serum potassium, valsartan.",
author = "Ranee Chatterjee and Laine Thomas and Laura Svetkey and Brancati, {Frederick L.} and Califf, {Robert M.} and David Edelman",
year = "2013",
month = "6",
doi = "10.1093/ajh/hpt016",
language = "English (US)",
volume = "26",
pages = "723--726",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Effects of changes in potassium with valsartan use on diabetes risk

T2 - Nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial

AU - Chatterjee, Ranee

AU - Thomas, Laine

AU - Svetkey, Laura

AU - Brancati, Frederick L.

AU - Califf, Robert M.

AU - Edelman, David

PY - 2013/6

Y1 - 2013/6

N2 - BACKGROUND Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium.METHODSWe analyzed data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, which randomized participants at risk for diabetes to either valsartan (up to 160mg daily) or no valsartan. Using Cox models, we evaluated the effect of valsartan on diabetes risk over a median of 4 years of follow-up and calculated the mediation effect of serum potassium as the difference in treatment hazard ratios from models excluding and including 1-year change in serum potassium. The 95% confidence interval (CI) for the difference in log hazard ratios was computed by bootstrapping.RESULTSThe hazard ratio for developing diabetes among those on valsartan vs. no valsartan was 0.866 (95% CI = 0.795-0.943) vs. 0.868 (95% CI = 0.797-0.945), after controlling for 1-year change in potassium. The bootstrap 95% CI for a difference in these log hazard ratios was not statistically significant (-0.003 to 0.009).CONCLUSIONSSerum potassium does not appear to significantly mediate the protective effect of valsartan on diabetes risk.

AB - BACKGROUND Low and low-normal serum potassium is associated with an increased risk of diabetes. We hypothesized that the protective effect of valsartan on diabetes risk could be mediated by its effect of raising serum potassium.METHODSWe analyzed data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial, which randomized participants at risk for diabetes to either valsartan (up to 160mg daily) or no valsartan. Using Cox models, we evaluated the effect of valsartan on diabetes risk over a median of 4 years of follow-up and calculated the mediation effect of serum potassium as the difference in treatment hazard ratios from models excluding and including 1-year change in serum potassium. The 95% confidence interval (CI) for the difference in log hazard ratios was computed by bootstrapping.RESULTSThe hazard ratio for developing diabetes among those on valsartan vs. no valsartan was 0.866 (95% CI = 0.795-0.943) vs. 0.868 (95% CI = 0.797-0.945), after controlling for 1-year change in potassium. The bootstrap 95% CI for a difference in these log hazard ratios was not statistically significant (-0.003 to 0.009).CONCLUSIONSSerum potassium does not appear to significantly mediate the protective effect of valsartan on diabetes risk.

KW - blood pressure

KW - diabetes

KW - hypertension

KW - risk

KW - serum potassium

KW - valsartan.

UR - http://www.scopus.com/inward/record.url?scp=84877781267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877781267&partnerID=8YFLogxK

U2 - 10.1093/ajh/hpt016

DO - 10.1093/ajh/hpt016

M3 - Article

C2 - 23417031

AN - SCOPUS:84877781267

VL - 26

SP - 723

EP - 726

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 6

ER -